India Drops MNC Negotiation Plans Without New Drug Price Controls
This article was originally published in PharmAsia News
India's delay in adopting a new drug price control plan has had a fallout effect on other plans to reduce the cost of imported drugs and medical devices. The government had planned to conduct negotiations with multinational drug makers, but canceled them when several ministries involved could not reach agreement on a new price control plan April 30. That failure was attributed to the Health Ministry, the same ministry that had planned to negotiate with the MNCs. (Click here for more
You may also be interested in...
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.